Rhythm Pharmaceuticals, Inc. - Special Call Transcript
Good morning, ladies and gentlemen, and welcome to the Rhythm Pharmaceuticals Conference Call to discuss the FDA approval of IMCIVREE. (Operator Instructions) As a reminder, this conference might be recorded.
I would now like to turn the call over to your host, Mr. David Connolly, Investor Relations and Corporate Communications. Sir?
Thank you, and thank you to everyone for joining us this morning to discuss the FDA's approval of IMCIVREE, setmelanotide, for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency.
Please note the press release issued earlier today and presentation we're using for this conference call are available online on the Investors & Media section of our website, rhythmtx.com.
Before we begin -- turning to Slide 2. Before we begin, I'd like to remind everybody that there will be forward-looking statements made on this call. Actual events or results could differ materially from those
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |